Skip to main content
Premium Trial:

Request an Annual Quote

PathGroup, CCE Partner to Provide PGx Capabilities to Community-based Oncologists

NEW YORK (GenomeWeb) – PathGroup and Cancer Clinics of Excellence today announced a partnership aimed at improving the ability of community-based oncologists to make personalized therapeutic decisions.

CCE has chosen PathGroup as a preferred laboratory service provider, and oncologists in CCE's network will now have access to tests and data generated by PathGroup using its SmartGenomics platform, which generates information about patient drug targets so physicians can make more precise, personalized therapeutic recommendations.

SmartGenomics uses several different technologies, including next-generation sequencing, array comparative genomic hybridization, immunohistochemistry, and fluorescent in situ hybridization, to profile a patient's cancer. The platform is supported by a bioinformatics pipeline from GenoSpace and Thomson Reuters, and provides oncologists with prognostic, predictive, and therapeutic information, and links the findings with clinical trial options, according to PathGroup.

Pranil Chandra, director of molecular pathology services at PathGroup, said in a statement that 80 percent of cancer patients are currently seen by community-based oncologists, and SmartGenomics provides them with access to academic-level medicine and cutting-edge therapies.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more